TY - JOUR T1 - How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation JO - Hematology, Transfusion and Cell Therapy T2 - AU - Perini,Guilherme Fleury AU - Fischer,Thais AU - Gaiolla,Rafael Dezen AU - Rocha,Talita Bueno AU - Bellesso,Marcelo AU - Teixeira,Larissa Lane Cardoso AU - Delamain,Marcia Torresan AU - Scheliga,Adriana Alves de Souza AU - Ribeiro,Glaciano Nogueira AU - Neto,Jorge Vaz AU - Baiocchi,Otávio Cesar Carvalho Guimaraes AU - Abdo,André Neder Ramires AU - Arrais-Rodrigues,Celso AU - Fogliatto,Laura M. AU - Bigni,Ricardo de Sá AU - Schaffel,Rony AU - Biasoli,Irene AU - Pereira,Juliana AU - Nabhan,Samir Kanaan AU - Souza,Cármino Antônio de AU - Chiattone,Carlos Sérgio SN - 25311379 M3 - 10.1016/j.htct.2020.04.002 DO - 10.1016/j.htct.2020.04.002 UR - http://www.htct.com.br/en-how-manage-lymphoid-malignancies-during-articulo-S253113792030033X AB - The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients. ER -